Provided by Tiger Trade Technology Pte. Ltd.

Bicycle Therapeutics Limited

5.30
-0.2400-4.33%
Volume:149.68K
Turnover:792.69K
Market Cap:367.65M
PE:-1.46
High:5.59
Open:5.58
Low:5.18
Close:5.54
52wk High:13.11
52wk Low:5.18
Shares:69.37M
Float Shares:3.08M
Volume Ratio:0.77
T/O Rate:4.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6211
EPS(LYR):-2.9039
ROE:-34.59%
ROA:-20.59%
PB:0.59
PE(LYR):-1.83

Loading ...

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday Trading

MT Newswires Live
·
Yesterday

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

MT Newswires Live
·
Feb 06

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading

MT Newswires Live
·
Feb 04

Bicycle Therapeutics Appoints Travis Thompson as CFO and Michael Method as CMO

Reuters
·
Feb 03

Bicycle Therapeutics Plc - Travis Thompson Appointed as CFO, Succeeds Alethia Young

THOMSON REUTERS
·
Feb 03

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

THOMSON REUTERS
·
Feb 03

Desert Control AS Appoints David Borah as Chief Financial Officer

Reuters
·
Feb 03

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading

MT Newswires Live
·
Jan 29

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 1.4% for Week

MT Newswires Live
·
Jan 24

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

MT Newswires Live
·
Jan 23

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

MT Newswires Live
·
Jan 21

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Rise 2% for Week

MT Newswires Live
·
Jan 17

Bicycle Therapeutics Showcases Innovative Precision-Guided Cancer Therapies in New Corporate Presentation

Reuters
·
Jan 12

Bicycle Therapeutics Announces Phase 2/3 Duravelo-2 Trial Update for Zelenectide Pevedotin Expected in Early 2026

Reuters
·
Jan 12

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

THOMSON REUTERS
·
Jan 12

Bicycle Therapeutics Plc - Initial Data for Duravelo-3 Phase 1/2 Trial Expected in H2 2026

THOMSON REUTERS
·
Jan 12

Bicycle Therapeutics Plc - Additional Epha2 Imaging Data Planned for H1 2026

THOMSON REUTERS
·
Jan 12

Bicycle Therapeutics Plc - Dose Selection From Phase 2/3 Duravelo-2 Trial, Approval Pathway Update Expected in 1Q 2026

THOMSON REUTERS
·
Jan 12

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading

MT Newswires Live
·
Jan 08

Bicycle Therapeutics CEO Kevin Lee Reports Disposal of Common Shares

Reuters
·
Jan 07